Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Baudax Bio
Deal Size : Undisclosed
Deal Type : Acquisition
Baudax Bio Acquires TeraImmune, Inc.
Details : The merger adds TeraImmune’s TI-168 asset to the Baudax portfolio, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.
Brand Name : TI-168
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 30, 2023
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Baudax Bio
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Undisclosed
Deal Type : Agreement
TeraImmune Extends CRADA for Development of Treg Expansion for Clinical Use
Details : Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.
Brand Name : TI-168
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TI-168 is a next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitor. The primary objectives are to evaluate the safety and feasibility of TI-168 and determine the maximum tolera...
Brand Name : TI-168
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 11, 2022
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?